BayCare Health System Site Map Social Media Contact Us
Morton Plant Mease  
Find a Doctor Classes & Events Pay My Bill Financial Assistance Policy Donate Get E-Newsletter
Services About Us Locations News Health Tools and Articles Careers Contact Us
Decrease (-) Restore Default Increase (+) font size
Bookmark and Share


Print This Page Print This Page    Email this to a Friend Email this to a Friend
2008 Press Releases
Morton Plant Hospital Cardiologists First in Tampa Bay Area to Use New Minimally Invasive Treatment for Heart Disease

PROMUS Drug-Eluting Stent Surgery Performed at Morton Plant Hospital

CLEARWATER, Fla., (July 10, 2008) - Morton Plant Hospital interventional cardiologists are the first in the Tampa Bay area to use the newly approved PROMUS™ Everolimus Eluting Coronary Stent System. The PROMUS stent was approved by the Food and Drug Administration (FDA) on July 2, 2008. Douglas Spriggs, M.D., interventional cardiologist implanted the new minimally invasive device for the treatment of heart disease during an angioplasty surgery at Morton Plant Hospital in Clearwater on July 7.

“Morton Plant Mease is nationally known for its premier heart care program. This is another first for our cardiologists and health system that demonstrates our commitment to quality, leading edge heart treatments for our patients,” said Philip K. Beauchamp, FACHE, president and chief executive officer, Morton Plant Mease Health Care."

Earlier this year Morton Plant cardiologists were among the first in the United States to treat patients with the Endeavor® Zotarolimus-Eluting Coronary Stent System.

“The addition of the PROMUS stent provides flexibility - more options in drug coatings, stent size and strut design to customize treatment to meet individual patient needs,” said Dr. Spriggs.

The PROMUS stent is a tiny metal scaffold or tube made of cobalt-chromium metal alloy with the drug everolimus contained in a thin coating. According to the device’s manufacturer, cobalt chromium allows for thinner metal struts that make the stent more flexible and easier for physicians to implant in coronary arteries. The stent is used during an angioplasty procedure to prop open and improve blood flow to arteries that have become narrowed or blocked due the gradual build-up of “plaque” or fatty cholesterol deposits. The drug-eluting stent delivers medication to the artery wall to reduce the chance that the artery will narrow again and require a repeat procedure.

PROMUS is a private-labeled XIENCE™ V Everolimus-Eluting Coronary Stent System manufactured by Abbott Laboratories and distributed by Boston Scientific. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.

Morton Plant Mease Heart Program Firsts:

  • First in Tampa Bay area to place drug-coated stents
  • First in Tampa Bay area to perform minimally invasive direct coronary artery bypass
  • First use of human donor valves in aortic valve replacement
  • First in Pinellas County to perform coronary angioplasty and valvuloplasty
  • First in Pinellas County to have an electrophysiology program for the diagnosis and treatment of arrhythmias
  • First in Pinellas County to perform cardiac ablation procedures
  • First in Pinellas County to perform coronary angioplasty via the radial artery
  • First cardiac surgery program in the Tampa Bay area to use concept of “universal beds”

Established in 1916, Morton Plant Hospital is a 687-bed facility. Our commitment to improving the health of everyone we serve is reflected in our community partnerships and many honors. In 2007, Morton Plant Hospital received a top national recognition for its work in open heart surgery and received the Premier Award for Quality in the area of Coronary Artery Bypass Graft. Since 1999 Morton Plant has been awarded 16 Top 100 Hospital designations in the areas of cardiovascular, stroke, orthopaedic and overall care by the Thomson 100 Top Hospitals: National Benchmarks for Success. Morton Plant also has received the Gold Seal of ApprovalTM for Primary Stroke Care from the Joint Commission on Accreditation of Healthcare Organizations (JCAHO). The hospitals of Morton Plant Mease Health Care are part of the first group of hospitals nationally to have earned re-certification of the Gold Seal of Approval™ for stroke care from the Joint Commission. Morton Plant also has partnered with H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa to provide research and services for cancer patients. In 2008, the hospital was awarded Magnet Designation for the second time by the American Nurses Credentialing Center, the most prestigious national recognition of excellence in nursing care. Morton Plant Hospital is located at 300 Pinellas Street, Clearwater, Fla., (727) 462-7000.

Nationally recognized for health care excellence, Morton Plant Mease Health Care is dedicated to providing community owned health care services that set the standard for high-quality, compassionate care. Morton Plant Mease Health Care is comprised of the following hospitals – Morton Plant, Clearwater; Mease Dunedin, Dunedin; Mease Countryside, Safety Harbor and Morton Plant North Bay, New Port Richey.

Contact: Beth Hardy (727) 298-6199 Phone, (727) 402-8113 Pager or Amy Morrow (727) 461-8538 Phone, (727) 402-5975 Pager